American Society of Hematology

Figure 1.

$Survival outcomes and cumulative incidence of relapsed/refractory disease in 56 patients after CD19 CAR T-cell therapy. (A) EFS (3-year EFS, 16.1%; 95% CI, 8.8-29). (B) OS (3-year OS, 26.6%; 95% CI, 17-42). (C) Cumulative incidence of R/R disease (1-year cumulative incidence of R/R disease, 67.9%; 95% CI, 53.6-78.6).$

Survival outcomes and cumulative incidence of relapsed/refractory disease in 56 patients after CD19 CAR T-cell therapy. (A) EFS (3-year EFS, 16.1%; 95% CI, 8.8-29). (B) OS (3-year OS, 26.6%; 95% CI, 17-42). (C) Cumulative incidence of R/R disease (1-year cumulative incidence of R/R disease, 67.9%; 95% CI, 53.6-78.6).

This Feature Is Available To Subscribers Only